KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $174,000 | -23.0% | 12,000 | -47.8% | 0.13% | -15.5% |
Q2 2022 | $226,000 | -33.3% | 23,000 | 0.0% | 0.16% | -25.1% |
Q1 2022 | $339,000 | +11.5% | 23,000 | 0.0% | 0.21% | +48.9% |
Q4 2021 | $304,000 | -24.2% | 23,000 | 0.0% | 0.14% | -5.4% |
Q3 2021 | $401,000 | -27.2% | 23,000 | 0.0% | 0.15% | +13.1% |
Q2 2021 | $551,000 | – | 23,000 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |